EGFR and non-small cell lung carcinoma: Studies have demonstrated that TBK1-IFN signaling can be enhanced by pemetrexed to improve the immunogenicity of EGFR-TKI resistant non-small cell lung cancer (NSCLC) cells with MET amplification (23).